Table 3.
All cohort | |||||||
---|---|---|---|---|---|---|---|
Demographics & comorbilities | Before Matching |
After Matching |
|||||
Tocilizumab (n = 197) | Control (n = 347) | Standardized difference (%) | Tocilizumab (n = 195) | Control (n = 347) | Standardized difference (%) | p Value | |
Age (mean, years) | 61.0 | 62.7 | −12.2 | 61.0 | 62.7 | −12.0 | 0.23 |
Male sex | 67.0 | 60.2 | 14.1 | 66.7 | 64.9 | 3.7 | 0.71 |
Obesity | 44.7 | 31.4 | 27.5 | 44.1 | 44.6 | −1.1 | 0.92 |
Asthma/COPD | 19.3 | 15.3 | 10.6 | 19.0 | 17.9 | 2.7 | 0.78 |
Cancer/Haematology malignancy | 9.6 | 11.0 | −4.3 | 9.7 | 9.0 | 2.5 | 0.80 |
Hypertension | 42.6 | 44.7 | −4.1 | 42.5 | 45.3 | −5.7 | 0.58 |
Diabetes | 21.8 | 27.1 | −12.2 | 22.1 | 29.1 | 16.6 | 0.12 |
Transplantation/VIH | 8.6 | 3.2 | 23.3 | 8.2 | 5.9 | 9.8 | 0.38 |
Chronic renal disease | 10.2 | 6.3 | 13.9 | 9.2 | 10.5 | −4.7 | 0.42 |
SpO2/FiO2 ratio (mean) | 209.6 | 282.5 | −77.4 | 210.4 | 202.4 | 8.5 | 0.67 |
Early administration cohort | |||||||
---|---|---|---|---|---|---|---|
Demographics & comorbilities | Tocilizumab (n = 147) | Control (n = 347) | Standardized difference (%) | Tocilizumab (n = 146) | Control (n = 347) | Standardized difference (%) | p Value |
Age (mean, years) | 60.0 | 62.7 | −19.4 | 60.1 | 60.8 | −4.7 | 0.69 |
Male sex | 64.6 | 60.2 | 9.1 | 64.4 | 63.0 | 2.8 | 0.81 |
Obesity | 44.9 | 31.4 | 28.0 | 44.5 | 37.3 | 14.9 | 0.21 |
Asthma/COPD | 17.7 | 15.3 | 6.5 | 17.8 | 18.5 | −1.8 | 0.88 |
Cancer/Haematology malignancy | 8.2 | 10.9 | −9.5 | 8.2 | 8.6 | −1.2 | 0.92 |
Hypertension | 42.9 | 44.7 | −3.6 | 42.5 | 45.5 | −6.2 | 0.60 |
Diabetes | 20.4 | 27.1 | −15.7 | 20.5 | 21.2 | −1.6 | 0.89 |
Transplantation/VIH | 5.4 | 3.2 | 11.2 | 4.8 | 5.5 | −3.4 | 0.79 |
Chronic renal disease | 7.5 | 6.3 | 4.5 | 6.8 | 6.2 | 2.7 | 0.81 |
SpO2/FiO2 ratio (mean) | 206.3 | 282.5 | −81.4 | 206.5 | 198.4 | 8.6 | 0.48 |
Data are presented as % unless a unit is given (years and ratio).